Publication Name	World Journal of Clinical Oncology
Manuscript ID	90334
Country	Spain

Received	2023-11-30 09:13
Peer-Review Started	2023-11-30 09:13
To Make the First Decision
Return for Revision	2024-01-06 07:10
Revised	2024-02-25 17:30
Second Decision	2024-04-08 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-04-08 06:30
Articles in Press	2024-04-08 06:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-26 10:18
Publish the Manuscript Online	2024-05-21 07:25

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Pembrolizumab autoimmune related diabetes: Moving forward, keep learning
Manuscript Source	Invited Manuscript
All Author List	Jose Angel Garcia, Diego Alcaraz, Esther Holgado and Felipe Couñago
ORCID	Author(s) ORCID Number Jose Angel Garcia http://orcid.org/0009-0001-6496-3282 Esther Holgado http://orcid.org/0000-0002-7008-7135 Felipe Couñago http://orcid.org/0000-0001-7233-0234
Funding Agency and Grant Number
Corresponding Author	Jose Angel Garcia, MMed, Attending Doctor, Department of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Joaquin Costa 28, Madrid 28002, Spain. jose.garcia@genesiscare.es
Key Words	Immune checkpoints; Pembrolizumab; Immunotherapy; Side effects; Endocrine system; Diabetes mellitus
Core Tip	Pembrolizumab-induced type 1 diabetes mellitus is a rare and potentially serious adverse event of immunotherapy, with a significant number of cases debuting abruptly and in a state of diabetic ketoacidosis without clear predisposing factors. Further research and strict follow-up by oncologists are fundamental tools for prevention and early treatment focusing on reducing the morbidity and mortality associated with this side effect.
Publish Date	2024-05-21 07:25
Citation	<p>Garcia JA, Alcaraz D, Holgado E, Couñago F. Pembrolizumab autoimmune related diabetes: Moving forward, keep learning. <i>World J Clin Oncol</i> 2024; 15(5): 576-579</p>
URL	https://www.wjgnet.com/2218-4333/full/v15/i5/576.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i5.576

Full Article (PDF)	WJCO-15-576-with-cover.pdf
Manuscript File	90334_Auto_Edited-YJP.docx
Answering Reviewers	90334-Answering reviewers.pdf
Audio Core Tip	90334-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90334-Conflict-of-interest statement.pdf
Copyright License Agreement	90334-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90334-Language certificate.pdf
Peer-review Report	90334-Peer-review(s).pdf
Scientific Misconduct Check	90334-Bing-Li L-2.png
Scientific Editor Work List	90334-Scientific editor work list.pdf
CrossCheck Report	90334-CrossCheck.png
CrossCheck Report	90334-CrossCheck report.pdf